Evidence map›Paper›PMID 40688999›Full record

ArticleCureus2025

Expanding the Phenotype: A Case Report of a Novel Alanyl-tRNA Synthetase 2 (AARS2) Homozygous Mutation in a 17-Month-Old Child.

Hadi A Helali, Samar Almuntaser

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hadi A HelaliPediatric Neurology, Al Jalila Children's Speciality Hospital, Dubai, ARE.
Samar AlmuntaserPediatric Neurology, Al Jalila Children's Speciality Hospital, Dubai, ARE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early developmental delay and progressive neurological symptoms are red flags when evaluating infants in neurology clinics. Early assessment and management are essential to improve outcomes, with genetic testing being a cornerstone. Even if initial genetic results were not suggestive, revisiting the reported variant and comparing it to the newly published reports of different phenotypes helps establish the clinical diagnosis, as the authors report in this case of a 17-month-old child who presented with global developmental delay and hypotonia and was found to have Alanyl-tRNA Synthetase 2 (

Indexed as

alanyl-trna synthetase 2dystoniametabolic diseasemitochondrial diseasenovel mutation

Identifiers

PMID40688999
PMCPMC12274783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.